OPKO Health (NASDAQ:OPK) Reaches New 12-Month High – Here’s What Happened

Shares of OPKO Health, Inc. (NASDAQ:OPK) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $2.04 and last traded at $1.94, with a volume of 15826287 shares changing hands. The stock had previously closed at $1.92.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Monday, March 3rd.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -10.00 and a beta of 1.63. The company has a 50-day moving average of $1.58 and a 200-day moving average of $1.56.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. As a group, equities research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 67,434 shares of the stock in a transaction on Friday, February 28th. The stock was purchased at an average cost of $1.71 per share, with a total value of $115,312.14. Following the purchase, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at approximately $364,745,476.08. The trade was a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders bought 1,389,971 shares of company stock valued at $2,124,442. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Private Advisor Group LLC grew its stake in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 25,000 shares during the period. Intech Investment Management LLC purchased a new stake in shares of OPKO Health during the 3rd quarter valued at $190,000. Integrated Investment Consultants LLC purchased a new stake in shares of OPKO Health during the 3rd quarter valued at $233,000. FMR LLC grew its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 217,450 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.